Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [4003] Nanoporous silicon delivery vectors for breast cancer imaging.
  [4005] Factors influencing false negative diagnosis of 3D-MRI in pre-operative breast cancer patients.
  [4006] Accuracy of MRI in selecting patients for breast conserving therapy after neoadjuvant chemotherapy.
  [4009] Comparative analysis of high resolution synchrotron radiation images of fibrocystic change and breast cancer.
  [4010] Automated classification of breast tissue microarray spots.
  [4011] Invasive and non-invasive breast cancer can be distinguished from normal mammary gland or benign breast tumor by apparent diffusion coefficient in magnetic resonance imaging.
  [4012] The impact of preoperative breast magnetic resonance imaging (MRI) on surgical decision-making in young patients with breast cancer.
  [4013] Diagnosis of mass forming lesions in combination with real-time tissue elastography.
  [4014] MRI findings in women with triple negative breast cancer.
  [4016] Quantitative MRI assessment of uninvolved breast tissue in patients with locally-advanced breast cancer undergoing neoadjuvant chemotherapy.
  [4018] The ability of preoperative magnetic resonance imaging to predict actual pathologic tumor size in women with newly diagnosed breast cancer.
  [4019] Evaluation of response to neoadjuvant chemotherapy in primary breast cancer using PET.
  [4020] The utility of preoperative breast magnetic resonance imaging in invasive breast cancer according to HER2 status.
  [4022] Accuracy of breast MRI in predicting tumor extent.
  [4023] Tumor volume analysis in clinical oncology.
  [4024] Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer.
  [4025] Different MR systems yield variable kinetic characteristics of malignant breast lesions.
  [4026] Evaluation of breast cancer using magnetic resonance imaging with diffusion sequence.
  [4027] The use of PET/CT in the management of breast cancer – the Royal Marsden Hospital experience.
  [4029] Apocrine carcinoma of the breast: clinical presentations, multimodality imaging findings and pathologic correlation.
  [4030] Notch-1 expression is not related to the percentage of CD326+ cells in bone marrow aspirates of patients with primary breast cancer.
  [4031] Primary tumor size is associated with ALDHbr breast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients.
  [4032] Clinical significance of bone marrow micrometastasis detected by nested RT-PCR for cytokeratin-19 in breast cancer patients.
  [4034] The insulin-like growth factor receptor I status in luminal A breast carcinoma.
  [4035] Pure apocrine carcinomas of the breast express ER-alpha 36, a novel alternatively spliced variant of human estrogen receptor-alpha (ER-alpha 66).
  [4037] Histologic markers of mammographic breast density: core-needle biopsy tissue from healthy volunteers.
  [4038] The relationship between tumour NF-kB expression, hormone status, and clinicopathological factors in primary invasive breast cancer.
  [4039] Validation of breast cancer biomarkers between a field immunohistochemistry laboratory in Nigeria and its US-based counterpart.
  [4041] The relationship between tumour NF-kB expression, hormone status and survival in primary invasive breast cancer.
  [4042] Role of extracellular signal-regulated kinase 5 (ERK5) in human breast cancer.
  [4044] CAPC expression correlates with breast tumor progression and invasion.
  [4052] SIRT7 expression and epigenetic status determine variability in telomere length in breast cancer.
  [4054] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
  [4056] Tumor necrosis factor transactivates ErbB2 in breast cancer cells.
  [4057] Recombinant human G-CSF increases invasiveness of breast cancer cells.
  [4059] Constitutive c-Met phosphorylation mediates growth in the absence of EGFR kinase activity in breast cancer cells dependent on EGFR expression for growth.
  [4060] Novel egg white based 3D cell culture system for breast cancer research.
  [4063] Mutation of PI3KCA in post-menopausal women with breast cancer and response to RAD001 treatment.
  [4066] Modulation of the Wnt/β-catenin pathway is associated with the basal-like breast cancer phenotype.
  [4067] Estrogen regulation of p53 isoforms in the human breast cancer cell line MCF7.
  [4069] Tumor suppressor PTEN signaling is up-regulated in mammary epithelial cells by soy isoflavone genistein: implications for breast cancer protection.
  [4070] Consistent TP53 mutations in BRCA1 and sporadic basal-like breast tumors, while infrequent in luminal BRCA1 tumors.
  [4071] Krupple-like factor 5 promotes breast cancer proliferation through activating fibroblast growth factor-binding protein transcription.
  [4072] Characterization of PTEN allelic status in a series of sporadic breast carcinomas demonstrating loss of 10q23.3 region by array-CGH.
  [4074] Assessment of breast cancer risk prediction models in a high-risk population.
  [4075] Sub-epithelial impedance: a new non-invasive method to measure mammographic density.
  [4076] Reliable data on 5- and 10-year survival in early-stage breast cancer provides accurate estimates of 15-year survival.
  [4077] Disparity between serum and nipple aspirate fluid (NAF) estradiol concentrations during the menstrual cycle.
  [4078] 17β-estradiol levels during an entire menstrual cycle in response to adult stature and insulin, of possible importance for breast cancer risk. The EBBA-I study.
  [4079] A new design of clinical trial – use of nomograms – illustration with local treatment of T2 tumors in the SEER database.
  [4080] Urinary estrogen metabolites in patients at high risk for breast cancer.
  [4081] Mammographic density and breast cancer risk in Chinese women.
  [4082] Mammographic density and breast cancer risk factors in Chinese women.
  [4083] Development and validation of Korean breast cancer risk assessment tool.
  [4084] Identification of functional transport in non lactating breast epithelium and its relationship to parity and menstrual cycle.
  [4086] Breast complaints and cancer: age stratified predictors of risk from a prospective database.
  [4087] Breast cancer patients unknowingly dosing themselves with estrogen by using topical moisturizers.
  [4088] Comparison of palonosetron (PALO) plus dexamethasone on day 1, with or without dexamethasone on days 2 and 3, in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients treated with anthracycline/cyclophosphamide regimens.
  [4090] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in HER2+ patients.
  [4091] Pre operative assessment enables the early detection and treatment of shoulder impairments related to breast cancer treatment.
  [4092] Long term follow up of acupuncture and hormone therapy on hot flushes and well-being in women with breast cancer – a prospective, randomized multi centre trial.
  [4094] Patient reported causes of fatigue in relation to adjuvant radiotherapy after breast conserving surgery.
  [4095] Response vs. nonresponse to treatment with erythropoiesis stimulating agents among breast cancer patients with anemia: findings from the European anemia cancer treatment study.
  [4096] Functional assessment of the arm following breast cancer treatment using the DASH survey.
  [4097] Lapatinib monotherapy in HER2+ relapsed or refractory inflammatory breast cancer (IBC): quality of life (QOL) assessment.
  [4098] Quality of life evaluation and decision-making after mastectomy for breast reconstruction of breast cancer patients.
  [4099] Integrated analysis of efficacy and safety of palonosetron (PALO) 0.75 mg IV for preventing chemotherapy-induced nausea and vomiting (CINV) in anthracycline and cyclophosphamide (AC/EC) combination chemotherapy in Japan: PALO Japanese breast cancer cooperative study group.
  [4100] Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved